SD Life Sciences Roundup: Takeda Consolidates, Startups Raise Cash
It’s been a busy week for startup funding, with Obalon Therapeutics, Aperio Technologies, Topera, and Ivera Medical closing on financing deals. We’ve also got drug development news from Ocera Therapeutics and MediciNova.
—Japan’s Takeda Pharmaceutical said it’s closing its center of excellence in South San Francisco, which has been focused on developing early stage antibody drugs, and consolidating its operations, now known as Takeda California, in San Diego. The company’s San Diego center of excellence, which is focused on structure-based drug discovery, has about 170 employees, according to a report by Gary Robbins of U-T San Diego. Keith Wilson, president and chief science officer of Takeda California, told the U-T that Takeda plans to add about 30 positions in San Diego by the end of the year.
—San Diego-based Qualcomm’s wireless health subsidiary, Qualcomm Life, named 25 members to an advisory council to help the business address key industry issues. The list includes Kleiner Perkins partner Brook Byers, X Prize founder Peter Diamandis, inventor Dean Kamen, Diego Miralles of Janssen Healthcare Innovation, Eric Topol of the Scripps Translational Science Institute, Psilos Ventures partner Lisa Suennen, and Larry Smarr, founding director of the California Institute for Telecommunications & Information Technology (Calit2).
—San Diego’s MediciNova (NASDAQ: MNOV) said its experimental asthma drug failed to meet the main goal of a second mid-stage trial. The drug developer said patients treated with its leading drug candidate, bedoradrine sulfate, showed significant improvement in other ways, but a sell off on Wall Street sent shares of MediciNova down by … Next Page »